Should There Be a Standard Therapy for Mantle Cell Lymphoma?

Mitchell R Smith


Future Oncol. 2011;7(2):227-237. 

In This Article


There is no standard therapy for MCL, nor should there be at this point in time. The ultimate goal is to understand the molecular pathogenesis of MCL, using our knowledge of the cyclin D1 and other involved pathways to individualize an effective targeted treatment. The current challenge to the physician is to select the optimal therapy for each individual patient. Given a relatively uncommon incurable disease, a clinical trial should always be encouraged. As appropriate choices can range from observation to variable intensity chemotherapy regimens to intensive chemotherapy with stem cell support, the choice must factor in the heterogeneity of MCL in terms of patient factors (e.g., age and comorbidites), clinical behavior (e.g., symptoms and pace of disease growth) and disease biology (e.g., proliferative rate and gene signature).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.